- Home
- PETS vs VSTM Comparison
PETS vs VSTM Comparison
Compare PETS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- VSTM
- Stock Information
- Founded
- PETS 1996
- VSTM 2010
- Country
- PETS United States
- VSTM United States
- Employees
- PETS 287
- VSTM N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- VSTM Health Care
- Exchange
- PETS Nasdaq
- VSTM Nasdaq
- Market Cap
- PETS 68.6M
- VSTM 425.9M
- IPO Year
- PETS N/A
- VSTM 2012
- Fundamental
- Price
- PETS $3.39
- VSTM $4.69
- Analyst Decision
- PETS Sell
- VSTM Strong Buy
- Analyst Count
- PETS 2
- VSTM 9
- Target Price
- PETS $3.35
- VSTM $12.63
- AVG Volume (30 Days)
- PETS 142.9K
- VSTM 2.5M
- Earning Date
- PETS 08-05-2025
- VSTM 08-07-2025
- Dividend Yield
- PETS N/A
- VSTM N/A
- EPS Growth
- PETS N/A
- VSTM N/A
- EPS
- PETS 0.02
- VSTM N/A
- Revenue
- PETS $247,010,000.00
- VSTM $10,000,000.00
- Revenue This Year
- PETS N/A
- VSTM $129.06
- Revenue Next Year
- PETS N/A
- VSTM $306.32
- P/E Ratio
- PETS $192.80
- VSTM N/A
- Revenue Growth
- PETS N/A
- VSTM N/A
- 52 Week Low
- PETS $2.90
- VSTM $2.10
- 52 Week High
- PETS $6.85
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- PETS 45.01
- VSTM 38.33
- Support Level
- PETS $3.13
- VSTM $4.01
- Resistance Level
- PETS $3.44
- VSTM $5.06
- Average True Range (ATR)
- PETS 0.18
- VSTM 0.35
- MACD
- PETS -0.00
- VSTM 0.04
- Stochastic Oscillator
- PETS 48.15
- VSTM 40.24
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.